State Street SPDR S&P Pharmaceuticals ETF
XPH
69 hedge funds and large institutions have $167M invested in State Street SPDR S&P Pharmaceuticals ETF in 2016 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 17 increasing their positions, 23 reducing their positions, and 4 closing their positions.
250% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 4
237% more call options, than puts
Call options by funds: $1.13M | Put options by funds: $334K
15% more funds holding
Funds holding: 60 → 69 (+9)
8% more capital invested
Capital invested by funds: $156M → $167M (+$11.7M)
0.97% more ownership
Funds ownership: 32.08% → 33.05% (+0.97%)
26% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$4.99M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$1.92M |
| 3 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$1.86M |
| 4 |
SI
Stephens Inc
Little Rock,
Arkansas
|
+$1.67M |
| 5 |
Jane Street
New York
|
+$1.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$4.3M |
| 2 |
WBG
Wharton Business Group
Malvern,
Pennsylvania
|
-$3.3M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$1.37M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.26M |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$986K |
XPH Hedge Fund Activity: Q3 2016 in Review
69 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q3 2016, worth a combined $167M — up 7.5% from $156M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new XPH positions and 4 closed out — a net gain of 10 holders — while 17 added to existing stakes and 23 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $4.99M. The largest seller was Morgan Stanley, cutting an estimated $4.3M.
- 69 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q3 2016, up from 60 in Q2 2016.
- Funds reported $167M of State Street SPDR S&P Pharmaceuticals ETF stock for Q3 2016, up 7.5% quarter-over-quarter.
- 14 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q3 2016 and 4 closed out, a net change of +10 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q3 2016 was Goldman Sachs, an estimated $4.99M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q3 2016 was Morgan Stanley, an estimated $4.3M sold.
Based on aggregated 13F filings for Q3 2016.